Profound Medical (PROF) reported Q2 2026 revenue of CAD 2.5M, up 12% from CAD 2.2M a year earlier. The company noted the reported result was influenced by TULSA product shipment timing—completed in July rather than June—suggesting some timing-driven distortion in the quarter’s reported growth.
Profound Medical (PROF) reported Q2 2026 revenue of CAD 2.5M, up 12% from CAD 2.2M a year earlier. The company noted the reported result was influenced by TULSA product shipment timing—completed in July rather than June—suggesting some timing-driven distortion in the quarter’s reported growth.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
